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Summary 
The prognosis of patients with lymphoid neoplasms is extremely variable. Reliable prognostic 
markers could allow the identification of patient sub ets that may benefit from alternate 
approaches.  
Epstein-Barr virus (EBV) is associated with approximately one third of Hodgkin lymphoma 
(HL) cases. EBV-DNA is often present in the plasma and whole blood of EBV-associated HL 
patients. However, the significance of EBV-DNA monit ring is debated. In a cohort of 165 
adult HL patients EBV-DNA viral load was prospectively monitored. Our results suggest that 
assessment of plasma EBV-DNA viral load might be of value for estimation of prognosis and 
follow-up of patients with EBV-positive HL. 
The role of the TP53 gene’s R72P polymorphism in NHL has been analyzed in several studies 
but it has not been studied in HL. We have evaluated th  role of R72P in 340 NHL and 298 
HL patients. Our results support the evidence that R72P is not a prognostic factor in 
Caucasian NHL patients, and they indicate its irrelevance for HL development or prognosis. 
In a study of 73 patients with chronic lymphocytic leukemia we have assessed IgVH 
mutational status, presence of mutation in TP53 gene and expression of CD38 and ZAP-70. 
Overall concordance between ZAP-70 expression and IgVH was 85%. Validation of the flow 
cytometry ZAP-70 detection was performed by comparison to the immunohistochemical 
analysis on histological sections and quantitative RT-PCR on the mRNA level; overall 
concordance was 86 %. Expression of ZAP-70 showed to be stable over time. 
 
